OREGA announces licensing of its first in class CD39 checkpoint inhibitor

actu_fonda_05
Four projects supported by our foundation
5 February 2016
Graphtys_actu
Graftys : initiation of post Marketing Surveillance program
16 November 2015

OREGA announces licensing of its first in class CD39 checkpoint inhibitor

Orega_actu

OREGA has entered into a worldwide licensing agreement with Innate Pharma.